Cardiac restrictions advised for osteoporosis drug

European regulators have decided against banning strontium ranelate because of its cardiovascular risks but say it should only be used to treat severe osteoporosis in patients with a high risk of fracture for whom other treatments are contraindicated.

In a decision that will no doubt be noted by the TGA in its current review of Protos,  the European Medicines Agency chose to ignore the advice from its Pharmacovigilance Risk Assessment Committee (PRAC) to suspend the medicine due to its cardiovascular risk.

While agreeing with the committee’s findings on the cardiovascular